

Atty Docket No. 2307U-237-3

PTO FAX NO.: 1-703-305-3014

FAX COPY
RECEIVED

AUG 06 1993

Attn: Examiner D. Barnd
Art Unit: 1813

PTO MALL 1

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following Supplemental Amendment in re application of JANET YAMAMOTO et al., Serial No. 07/739,014, filed on July 31, 1991, is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 3

Dated: August 5, 1993


Susan L. Kleinman

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 326-2422**

TOWNSEND and TOWNSEND KHOURIE and CREW
Steuart Street Tower, 20th Floor
One Market Plaza
San Francisco, California 94105
Telephone: (415) 326-2400
Fax: (415) 326-2422

BEST AVAILABLE COPY

via FACSIMILE

PATENT

Attorney Docket No. 2307U-237-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JANET YAMAMOTO et al.

Examiner: D. Barnd

Serial No.: 07/739,014

Art Unit: 1813

Filed: July 31, 1991

SUPPLEMENTAL RESPONSEFor: METHODS AND COMPOSITIONS
FOR VACCINATING AGAINST
FELINE IMMUNODEFICIENCY
VIRUSCommissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In further response to the Office Action dated May 14,
1993, please amend the above-referenced application as follows:In The Claims

Please cancel claims 1-4.

3. (Amended) A vaccine composition as in claim 14
[1], further comprising an adjuvant.END
Please cancel claims 6-13.

14. (As filed) A vaccine against feline immunodeficiency virus infection comprising an immunogen selected from the group consisting of inactivated whole FIV and an inactivated FIV-expressing cell line, wherein said immunogen elicits an immune response protective against infection by FIV when administered to a susceptible host in an amount effective to elicit such response.

15. (As filed) A method for protecting a susceptible cat against feline immunodeficiency virus infection, said method comprising administering to said cat a vaccine comprising an immunogen selected from the group consisting of inactivated whole FIV and an inactivated FIV-expressing cell line, in an amount effective to elicit an immune response protective against infection by FIV.

BEST AVAILABLE COPY

47